4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Jefferies Financial Group
by Kim Johansen · The Markets DailyJefferies Financial Group restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research note published on Monday, Marketbeat.com reports. Jefferies Financial Group currently has a $21.00 price objective on the stock, down from their prior price objective of $40.00.
Other equities research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Royal Bank Of Canada raised their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Barclays started coverage on shares of 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Finally, Wall Street Zen raised shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.
View Our Latest Stock Report on FDMT
4D Molecular Therapeutics Stock Performance
4D Molecular Therapeutics stock opened at $9.87 on Monday. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $12.34. The stock’s 50 day simple moving average is $9.02 and its two-hundred day simple moving average is $9.27. The stock has a market cap of $503.86 million, a price-to-earnings ratio of -4.08 and a beta of 2.94.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.96. The firm had revenue of $85.09 million during the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%. On average, analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.
Hedge Funds Weigh In On 4D Molecular Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $41,000. Quadrature Capital Ltd purchased a new position in shares of 4D Molecular Therapeutics during the second quarter valued at approximately $42,000. Farther Finance Advisors LLC raised its holdings in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.